Summary

In patients with acute coronary syndrome (ACS) who are undergoing coronary artery bypass grafting (CABG), treatment with ticagrelor within 7 days prior to surgery is associated with lower rates of mortality after CABG and comparable rates of CABG-related bleeding compared with clopidogrel. Findings from a retrospective analysis of the nonrandomized subgroup of patients who required CABG (n=1261) within 7 days of last intake of study drug from the Platelet Inhibition and Patient Outcomes [PLATO; NCT00391872] study, comparing ticagrelor and clopidogrel.